Impaired performance of female APP/PS1 mice in the morris water maze is coupled with increased Aβ accumulation and microglial activation

Neurodegenerative Diseases

Volumn 11, Issue 1, 2012, Pages 33-41

  Gallagher, J J ^a   Minogue, A M ^a   Lynch, M A ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Secretase 1; Alzheimer's disease; Insulin degrading enzyme; Neuroinflammation; Spatial memory

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; CD11B ANTIGEN; CD68 ANTIGEN; CONGO RED; INSULINASE; INTERLEUKIN 1BETA; MESSENGER RNA; PRESENILIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL ACTIVATION; COGNITION; CONTROLLED STUDY; FEMALE; LEARNING; MALE; MAZE TEST; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPATIAL MEMORY;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD; ANTIGENS, CD11B; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ASPARTIC ACID ENDOPEPTIDASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; INSULYSIN; INTERLEUKIN-1BETA; LEARNING DISORDERS; MALE; MAZE LEARNING; MICE; MICE, TRANSGENIC; MICROGLIA; NEPRILYSIN; PRESENILIN-1; REACTION TIME; RNA, MESSENGER; SEX CHARACTERISTICS;

EID: 84866357260     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000337458     Document Type: Article

References (52)

1. Cagnin A, et al: In-vivo measurement of activated microglia in dementia. Lancet 2001; 358: 461-467. (Pubitemid 32769854)
2. Breitner JC: The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med 1996; 47: 401-411. (Pubitemid 26138900)
3. Varvel NH, et al: NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J Clin Invest 2009; 119: 3692-3702.
4. Heneka MT, et al: Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease. Curr Alzheimer Res 2011; 8: 115-131.
5. Griffin WS, et al: Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989; 86: 7611-7615. (Pubitemid 19254506)
6. Wood JA, et al: Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res 1993; 629: 245-252. (Pubitemid 23337798)
7. Cacabelos R, et al: Serum tumor necrosis factor (TNF) in Alzheimer's disease and multiinfarct dementia. Methods Find Exp Clin Pharmacol 1994; 16: 29-35. (Pubitemid 24067673)
8. Motta M, et al: Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression. Immunol Lett 2007; 114: 46-51. (Pubitemid 47625597)
9. Paresce DM, Ghosh RN, Maxfield FR: Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron 1996; 17: 553-565. (Pubitemid 26322226)
10. Ard MD, et al: Scavenging of Alzheimer's amyloid beta-protein by microglia in culture. J Neurosci Res 1996; 43: 190-202. (Pubitemid 26044233)
11. DeWitt DA, et al: Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease. Exp Neurol 1998; 149: 329-340. (Pubitemid 28115071)
12. Fiala M, et al: Ineffective phagocytosis of amyloid- beta by macrophages of Alzheimer's disease patients. J Alzheimers Dis 2005; 7: 221-232; discussion 255-262. (Pubitemid 40917251)
13. Zaghi J, et al: Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. Acta Neuropathol 2009; 117: 111-124.
14. Wang DS, Dickson DW, Malter JS: Beta-amyloid degradation and Alzheimer's disease. J Biomed Biotechnol 2006; 2006: 58406.
15. Iwata N, et al: Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci 2004; 24: 991-998. (Pubitemid 38146610)
16. Howell S, Nalbantoglu J, Crine P: Neutral endopeptidase can hydrolyze beta-amyloid (1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides 1995; 16: 647-652.
17. Kanemitsu H, Tomiyama T, Mori H: Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett 2003; 350: 113-116. (Pubitemid 37101425)
18. Liu Y, et al: In vitro and in vivo degradation of Abeta peptide by peptidases coupled to erythrocytes. Peptides 2007; 28: 2348-2355. (Pubitemid 350116309)
19. Shirotani K, et al: Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphanand phosphoramidon- sensitive endopeptidases. J Biol Chem 2001; 276: 21895-21901.
20. Iwata N, et al: Metabolic regulation of brain Abeta by neprilysin. Science 2001; 292: 1550-1552. (Pubitemid 32493424)
21. El-Amouri SS, et al: Neprilysin protects neurons against Abeta peptide toxicity. Brain Res 2007; 1152: 191-200. (Pubitemid 46802503)
22. Hemming ML, et al: Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med 2007; 4:e262.
23. Leissring MA, et al: Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron, 2003; 40: 1087-1093. (Pubitemid 38032786)
24. Marr RA, et al: Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 2003; 23: 1992-1996. (Pubitemid 36368884)
25. Kurochkin IV: Amyloidogenic determinant as a substrate recognition motif of insulindegrading enzyme. FEBS Lett 1998; 427: 153-156. (Pubitemid 28225048)
26. Farris W, et al: Insulin-degrading enzyme regulates the levels of insulin, amyloid betaprotein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003; 100: 4162-4167. (Pubitemid 36418174)
27. Sondag CM, Dhawan G, Combs CK: Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia. J Neuroinflammation 2009; 6: 1.
28. Brookmeyer R, Gray S, Kawas C: Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Publ Health 1998; 88: 1337-1342. (Pubitemid 28402270)
29. Hy LX, Keller DM: Prevalence of AD among whites: a summary by levels of severity. Neurology 2000; 55: 198-204. (Pubitemid 30604618)
30. Vina J, Lloret A: Why women have more Alzheimer's disease than men: gender and mitochondrial toxicity of amyloid-beta peptide. J Alzheimers Dis 2010; 20(suppl 2):527-533.
31. Qiu C, Kivipelto M, von Strauss E: Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009; 11: 111-128.
32. Hirata-Fukae C, et al: Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res 2008; 1216: 92-103.
33. Wang J, et al: Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol Dis 2003; 14: 318-327. (Pubitemid 37543511)
34. Maynard CJ, et al: Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer beta-amyloid pathology. J Inorg Biochem 2006; 100: 952-962.
35. Placanica L, Zhu L, Li YM: Gender- and agedependent gamma-secretase activity in mouse brain and its implication in sporadic Alzheimer disease. PLoS One 2009; 4:e5088.
36. Schafer S, et al: Gender dependent APP processing in a transgenic mouse model of Alzheimer's disease. J Neural Transm 2007; 114: 387-394. (Pubitemid 46328658)
37. Miners JS, et al: Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 2008; 18: 240-252.
38. Yasojima K, et al: Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of betaamyloid peptide. Neurosci Lett 2001; 297: 97-100.
39. Lynch MA: The multifaceted profile of activated microglia. Mol Neurobiol 2009; 40: 139-156.
40. Gallagher JJ, et al: Modest amyloid deposition is associated with iron dysregulation, microglial activation, and oxidative stress. J Alzheimers Dis 2012; 28: 147-161.
41. Meyer-Luehmann M, et al: Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008; 451: 720-724. (Pubitemid 351220570)
42. Koenigsknecht-Talboo J, Landreth GE: Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 2005; 25: 8240-8249. (Pubitemid 41292118)
43. Weiner HL, Frenkel D: Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 2006; 6: 404-416.
44. Shaftel SS, et al: Sustained hippocampal IL- 1beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 2007; 117: 1595-1604. (Pubitemid 46871344)
45. Walsh DM, et al: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-539. (Pubitemid 34288854)
46. Dudal S, et al: Inflammation occurs early during the Abeta deposition process in TgCRND8 mice. Neurobiol Aging 2004; 25: 861-871. (Pubitemid 38813166)
47. Gordon MN, et al: Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 2002; 173: 183-195. (Pubitemid 34151370)
48. Puolivali J, et al: Hippocampal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice. Neurobiol Dis 2002; 9: 339-347. (Pubitemid 34442081)
49. Cao D, et al: Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem 2007; 282: 36275-36282.
50. Melnikova T, et al: Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience 2006; 141: 1149-1162. (Pubitemid 44128685)
51. Clinton LK, et al: Age-dependent sexual dimorphism in cognition and stress response in the 3 ! Tg-AD mice. Neurobiol Dis 2007; 28: 76-82. (Pubitemid 47429975)
52. King DL, et al: Progressive and genderdependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav Brain Res 1999; 103: 145-162. (Pubitemid 29417998)